The Swiss life sciences supplier’s pharma & biotech segment saw revenue increased 15.9% in 2016 to CHF1.85bn ($1.84bn) with core earning growing 40.8% to CHF400m.
Lonza said the gains were driven by strong momentum in its mammalian manufacturing business – which produces biopharmaceuticals for drug industry customers - and a “by a significant upward trend in all other technologies and modalities.”
The firm also highlighted manufacturing contracts with Kodiak Sciences, bluebird bio and Clovis Oncology signed during the year.
Company-wide revenues increased 8.7% to CHF4.13bn while earning grew 24.2% to CHF651m.
Lonza will hold its conference call later today.